Simulect Euroopa Liit - eesti - EMA (European Medicines Agency)

simulect

novartis europharm limited - basiiliksimab - graft rejection; kidney transplantation - immunosupressandid - simulect on näidustatud ägeda äratõukereaktsiooni de novo allogeense neeru siirdamise korral täiskasvanud ja lapsed (1-17-aastastel patsientidel) profülaktika. seda kasutatakse samaaegselt koos ciclosporin jaoks microemulsion - ja kortikosteroidi põhinev immunosupressiooni, patsientidel paneel reageerivaid antikehi on vähem kui 80%, või triple hooldus immunosupressiivsed raviskeemi, mis sisaldab ciclosporin jaoks microemulsion, kortikosteroidid ja kas asatiopriin või mükofenolaatmofetiili.

CASIRIVIMAB AND IMDEVIMAB 120MG/ML infusioonilahuse kontsentraat Eesti - eesti - Ravimiamet

casirivimab and imdevimab 120mg/ml infusioonilahuse kontsentraat

roche pharma ag - kasirivimab+imdevimab - infusioonilahuse kontsentraat - 120mg+120mg 1ml 20ml 2tk

CASIRIVIMAB AND IMDEVIMAB 120MG/ML infusioonilahuse kontsentraat Eesti - eesti - Ravimiamet

casirivimab and imdevimab 120mg/ml infusioonilahuse kontsentraat

genentech inc. - kasirivimab+imdevimab - infusioonilahuse kontsentraat - 120mg+120mg 1ml 20ml 2tk

Ronapreve Euroopa Liit - eesti - EMA (European Medicines Agency)

ronapreve

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - suguhormoonid ja immunoglobuliinid, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. vt lõigud 4. 4 ja 5.

Idefirix Euroopa Liit - eesti - EMA (European Medicines Agency)

idefirix

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunosupressandid - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Nulojix Euroopa Liit - eesti - EMA (European Medicines Agency)

nulojix

bristol-myers squibb pharma eeig - belatatsept - graft rejection; kidney transplantation - immunosupressandid - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.

CERTICAN 0,75 MG TABLETID tablett Eesti - eesti - Ravimiamet

certican 0,75 mg tabletid tablett

novartis baltics sia - everoliimus - tablett - 0,75mg 250tk; 0,75mg 100tk; 0,75mg 60tk; 0,75mg 50tk

CERTICAN 1 MG TABLETID tablett Eesti - eesti - Ravimiamet

certican 1 mg tabletid tablett

novartis baltics sia - everoliimus - tablett - 1mg 60tk; 1mg 250tk; 1mg 50tk; 1mg 100tk

CERTICAN 0,25 MG TABLETID tablett Eesti - eesti - Ravimiamet

certican 0,25 mg tabletid tablett

novartis baltics sia - everoliimus - tablett - 0,25mg 50tk; 0,25mg 60tk; 0,25mg 250tk

CERTICAN 0,1 MG DISPERGEERUVAD TABLETID dispergeeruv tablett Eesti - eesti - Ravimiamet

certican 0,1 mg dispergeeruvad tabletid dispergeeruv tablett

novartis baltics sia - everoliimus - dispergeeruv tablett - 0,1mg 100tk; 0,1mg 60tk